• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: EDWARDS LIFESCIENCES LLC CARPENTIER-EDWARDS PERIMOUNT MAGNA EASE PERICARDIAL AORTIC BIOPROSTHESIS; REPLACEMENT HEART VALVE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

EDWARDS LIFESCIENCES LLC CARPENTIER-EDWARDS PERIMOUNT MAGNA EASE PERICARDIAL AORTIC BIOPROSTHESIS; REPLACEMENT HEART VALVE Back to Search Results
Model Number 3300TFX
Medical Device Problem Code Calcified (1077)
Health Effect - Clinical Code Insufficient Information (4580)
Date of Event 05/21/2025
Type of Reportable Event Serious Injury
Additional Manufacturer Narrative
H11: additional manufacturer narrative: the investigation is still in progress; therefore, a conclusion has yet to be established.A supplemental report will be submitted accordingly upon investigation completion.Edwards will continue to review and monitor all reported events.Trends are monitored on a monthly basis and if action is required, appropriate investigation will be performed.
 
Event or Problem Description
It was learned through implant patient registry and medical records that a patient with a 29mm 3300tfx aortic valve was explanted after an implant duration of 5 years due to calcification with moderate to severe regurgitation with moderate stenosis.The explanted valve was replaced with a 25mm 11500a inspiris resilia aortic valve.The patient tolerated the procedure well and was transported to open heart recovery unit in stable condition.Per pathology, explanted aortic valve had degenerative changes with densely calcified bright yellow deposits.This is a 62-year-old male patient.Edwards lifesciences maintains an implant patient registry.This registry is a patient tracking mechanism for serialized edwards implantable devices (bioprosthetic heart valves and annuloplasty rings), rather than a true post-market surveillance registry.Through the registry, edwards is notified when these devices are implanted.In addition, patient and/or device status may be reported to the registry via the implantation data cards.The information is received from various sources (e.G.Surgeon, hospital, and patient family members) and is not received in the form of a conventional 'customer complaint'.The information reported may or may not be related to the edwards device.
 
Additional Manufacturer Narrative
H11: additional manufacturer narrative: updated sections: g3, g6, h2, h6 (type of investigation).Corrected sections: h6 (component code, investigation findings and investigation conclusions).Svd is a logical and expected consequence of the chemical, mechanical, and immunological processes associated with bhv implantation.The common endpoint of all these factors is calcification and degradation.Svd is an acquired condition, intrinsic to bioprosthetic valves, characterized by deterioration of the leaflets or supporting structures, leading to thickening, calcification, tearing, or disruption of the prosthetic valve materials.These changes result in valvular dysfunction manifesting as stenosis and/or regurgitation with a consequent drop in hemodynamic efficacy of the valve.Prior investigations and extensive literature review have shown that svd is predominantly related to patient factors and implant duration rather than to manufacturing issues.Events related to device design, manufacturing, or use error tend to manifest at an earlier implant duration.There is no evidence to suggest a manufacturing defect caused or contributed to the reported event.Based on the information available, the most likely root cause is patient factors, including coronary artery disease.The device history record (dhr) review was completed, and this device passed all manufacturing and sterilization inspections prior to release for distribution.There were no issues identified that would have impacted this event.Edwards will continue to review and monitor all reported events.Trends are monitored on a monthly basis and if action is required, appropriate investigation will be performed.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
CARPENTIER-EDWARDS PERIMOUNT MAGNA EASE PERICARDIAL AORTIC BIOPROSTHESIS
Common Device Name
REPLACEMENT HEART VALVE
Manufacturer (Section D)
EDWARDS LIFESCIENCES LLC
one edwards way
irvine CA 92614
Manufacturer (Section G)
EDWARDS LIFESCIENCES LLC
one edwards way
irvine CA 92614
Manufacturer Contact
saurav singh
1 edwards way
mle fl2 - office m2013
irvine, CA 92614
9492506615
MDR Report Key22304451
Report Number2015691-2025-05065
Device Sequence Number20855866
Product Code DYE
UDI-Device Identifier00690103176179
UDI-Public(01)00690103176179(17)210613
Combination Product (Y/N)N
Initial Reporter StateWV
Initial Reporter CountryUS
PMA/510(K) Number
P860057
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2020
Device Explanted Year2025
Serviced by Third Party (Y/N)Unknown
Reporter Type Manufacturer
Report Source Other
Initial Reporter Occupation Physician
Type of Report Initial,Followup
Report Date (Section B) 07/28/2025
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Operator of Device Health Professional
Device Expiration Date06/13/2021
Device Model Number3300TFX
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? No
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 05/30/2025
Supplement Date Received by Manufacturer07/23/2025
Initial Report FDA Received Date06/22/2025
Supplement Report FDA Received Date07/28/2025
Was Device Evaluated by Manufacturer? (Y/N) No
Date Device Manufactured06/14/2017
Is the Device Labeled for Single Use? (Y/N) Yes
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Outcome Attributed to Adverse Event Life Threatening; Hospitalization; Required Intervention;
Patient Age62 YR
Patient SexMale
-
-